FindTrial
Sign In

Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertension

Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertension

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220801
Enrollment
Unknown
Registered
2009-08-12
Start date
2009-08-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension

Interventions

investigational material(s) Generic name etc : AT-877ER INN of investigational material : Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigational mat

Sponsors

ASAHI KASEI PHARMA CORPORATION
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged 20 years and over at the time of consent (2) Able to be hospitalized at the start and the end of study treatment; however, subjects may be treated on both an inpatient and outpatient basis at the time of consent (3) Class I to III according to the World Health Organization (WHO) Pulmonary Hypertension Functional Classification at the time of consent

Exclusion criteria

Exclusion criteria: (1) Use of catecholamines and/or PDE3 inhibitors for the treatment of cardiac failure at the time of consent (2) Serious cardiac disorder not caused by pulmonary arterial hypertension, such as angina pectoris, myocardial infarction and myocarditis (3) Previous participation in this study

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026